Enlyton, Ltd, initiated a pilot study for BioCrystal’s outpatient cancer screening test, which offers promise for use in determining the existence and extent of tumor invasion, and for monitoring the effectiveness of anti-cancer treatment. This study, conducted in cooperation with The Ohio State University, is expected to be completed in the first quarter 2008. |
